AGLE
Price:
$12.01
Market Cap:
$5.04B
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
AGLE
According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.97. This represents a change of -9.42% compared to the average of 9.90 of the last 4 quarters.
The mean historical Current Ratio of Aeglea BioTherapeutics, Inc. over the last ten years is 9.15. The current 8.97 Current Ratio has changed 9.70% with respect to the historical average. Over the past ten years (40 quarters), AGLE's Current Ratio was at its highest in in the June 2016 quarter at 22.88. The Current Ratio was at its lowest in in the June 2023 quarter at 1.03.
Average
9.15
Median
9.44
Minimum
4.06
Maximum
16.75
Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 151.42%
Maximum Annual Current Ratio = 16.75
Minimum Annual Increase = -46.11%
Minimum Annual Current Ratio = 4.06
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 13.25 | 17.75% |
| 2024 | 11.26 | 5.39% |
| 2023 | 10.68 | 151.42% |
| 2022 | 4.25 | -13.47% |
| 2021 | 4.91 | -46.11% |
| 2020 | 9.11 | 124.47% |
| 2019 | 4.06 | -45.80% |
| 2018 | 7.49 | -23.35% |
| 2017 | 9.77 | -41.69% |
| 2016 | 16.75 | 10.40% |
The current Current Ratio of Aeglea BioTherapeutics, Inc. (AGLE) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
11.73
5-year avg
8.87
10-year avg
9.15
Aeglea BioTherapeutics, Inc.’s Current Ratio is greater than bluebird bio, Inc. (0.55), greater than GreenLight Biosciences Holdings (2.01), greater than Lunai Bioworks Inc. (0.19), less than AlloVir, Inc. (12.14), greater than Rein Therapeutics Inc. (0.40), greater than ERYTECH Pharma S.A. (1.06), less than Kronos Bio, Inc. (12.93), less than Magenta Therapeutics, Inc. (29.25), greater than TCR2 Therapeutics Inc. (2.77), greater than Pluristem Therapeutics Inc. (0.33),
| Company | Current Ratio | Market cap |
|---|---|---|
| 0.55 | $48.67M | |
| 2.01 | $45.43M | |
| 0.19 | $32.92M | |
| 12.14 | $49.48M | |
| 0.40 | $26.42M | |
| 1.06 | $47.38M | |
| 12.93 | $53.65M | |
| 29.25 | $42.44M | |
| 2.77 | $58.11M | |
| 0.33 | $40.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Aeglea BioTherapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the highest Current Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 3-year average Current Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 5-year average Current Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?
How does the current Current Ratio for Aeglea BioTherapeutics, Inc. (AGLE) compare to its historical average?